Medical News / Reporting from ESC 2023: Semaglutide for HFpEF? Breaking Down the STEP-HFpEF Trial, with Javed Butler, MD

The understanding and management of heart failure with preserved ejection fraction (HFpEF) has undergone a transformation in recent years and the STEP-HFpEF at the European Society of Cardiology (ESC) Congress 2023 provides the latest evidence this transformation is still ongoing. A randomized, double-blind, placebo-controlled trial conducted at 96 sites in Asia, Europe, and North and South America, the STEP-HFpEF trial assessed the effects of semaglutide 2.4 mg (Wegovy) against placebo therapy on symptoms and functional status in adults with obesity and HFpEF. The trial enrolled 529 participants, with 266 and 263 randomized to the semaglutide 2.4 mg and placebo arms, respectively. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful ... read more
At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its ... read more
Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the ... read more
For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to ... read more